Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials

BMC Cardiovascular Disorders

Xiaoying Li¹  Wei Wei²  Wei Xin¹ 

[1] First Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, Peoples Republic of China;Department of pathophysiology, Medical College of Nankai University, Tianjin, Peoples Republic of China

关键词: Meta-analysis;    Inflammatory markers;    Heart failure;    Omega 3 polyunsaturated fatty acids;    Fish oil;   

Others  :  1084389
DOI  :  10.1186/1471-2261-12-77

 received in 2012-04-10, accepted in 2012-09-18,  发布年份 2012

【 摘 要 】

Background

Effects of fish oil on systematic inflammation in chronic heart failure remain unclear. In this meta-analysis, we aimed to evaluate the influence of fish oil supplementation on circulating levels of inflammatory markers in patients with chronic heart failure.

Methods

Human randomized controlled trials, which compared the effects of fish oil supplementation with placebo in patients with chronic heart failure, were identified by systematic search of Medline, Embase, Cochrane’s library and references cited in related reviews and studies up to November 2011. Outcome measures comprised the changes of circulating inflammatory markers. Meta-analysis was performed with the fixed-effect model or random-effect model according to the heterogeneity.

Results

A total of seven trials with eight study arms were included. The pooled results indicated circulating levels of tumor necrosis factor α (SMD = -0.62, 95% CI -1.08 to -0.16, p = 0.009), interleukin 1 (SMD = -1.24, 95% CI -1.56 to -0.91, p < 0.001) and interleukin 6 (SMD = -0.81, 95% CI -1.48 to -0.14, p = 0.02) were significantly decreased after fish oil supplementation; however, high sensitivity C reactive protein, soluble intracellular adhesion molecular 1 and vascular cell adhesion molecular 1 were not significantly affected. Meta-regression and subgroup analysis results suggested the difference in dose of fish oil and follow-up duration might influence the effects of fish oil on tumor necrosis factor α and interleukin 6. Greater reduction of these two markers might be achieved in patients taking fish oil of a higher dose (over 1000 mg/day) or for a longer duration (over 4 months).

Conclusions

Limited evidence suggests anti-inflammation may be a potential mechanism underlying the beneficial effects of fish oil for chronic heart failure. Further large-scale and adequately powered clinical trials are needed to confirm these effects.

【 授权许可】

   
2012 Xin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Braunwald E, Bristow MR: Congestive heart failure: fifty years of progress. Circulation 2000, 102:IV14-IV23.
• [2]Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
• [3]Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, Van VDJ, Atar D, Hoes AW, et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
• [4]Fang J, Mensah GA, Croft JB, Keenan NL: Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008, 52:428-434.
• [5]Najafi F, Jamrozik K, Dobson AJ: Understanding the 'epidemic of heart failure': a systematic review of trends in determinants of heart failure. Eur J Heart Fail 2009, 11:472-479.
• [6]Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, et al.: Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-18e209.
• [7]Witte KK, Clark AL: Fish oils–adjuvant therapy in chronic heart failure. Eur J Cardiovasc Prev Rehabil 2004, 11:267-274.
• [8]Marchioli R, Silletta MG, Levantesi G, Pioggiarella R, Tognoni G: N-3 polyunsaturated fatty acids in heart failure: mechanisms and recent clinical evidence. Cell Mol Biol (Noisy-le-Grand) 2010, 56:110-130.
• [9]Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
• [10]Anker SD, Von HS: Inflammatory mediators in chronic heart failure: an overview. Heart 2004, 90:464-470.
• [11]Bozkurt B, Mann DL, Deswal A: Biomarkers of inflammation in heart failure. Heart Fail Rev 2010, 15:331-341.
• [12]Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, Lin SJ, Young MS: The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail 2003, 5:507-516.
• [13]Araujo JP, Lourenco P, Azevedo A, Frioes F, Rocha-Goncalves F, Ferreira A, Bettencourt P: Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 2009, 15:256-266.
• [14]Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, et al.: Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009, 11:119-129.
• [15]Tang WH, Samara MA: Polyunsaturated fatty acids in heart failure: should we give more and give earlier. J Am Coll Cardiol 2011, 57:880-883.
• [16]Mehra MR, Lavie CJ, Ventura HO, Milani RV: Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant 2006, 25:834-838.
• [17]O'Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS: Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 2006, 97:1127-1130.
• [18]Nodari S, Metra M, Milesi G, Manerba A, Cesana BM, Gheorghiade M, Dei CL: The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther 2009, 23:5-15.
• [19]Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, Zhang DF, Zhang H: Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res 2009, 37:1831-1841.
• [20]Eschen O, Christensen JH, LA RMT, Romano P, Sala P, Schmidt EB: Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell Mol Biol (Noisy-le-Grand) 2010, 56:45-51.
• [21]Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S: Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost 2011, 106:457-465.
• [22]Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R: Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011, 161(915):e1-e9.
• [23]Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei CL: Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011, 57:870-879.
• [24]Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13. BioMed Central Full Text
• [25]Higgins JPT, Green S (Eds): In Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org webcite
• [26]Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 1998, 352:609-613.
• [27]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
• [28]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
• [29]Egger M, Davey SG, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [30]Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS: Fish intake and risk of incident heart failure. J Am Coll Cardiol 2005, 45:2015-2021.
• [31]Yamagishi K, Nettleton JA, Folsom AR: Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008, 156:965-974.
• [32]Levitan EB, Wolk A, Mittleman MA: Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J 2009, 30:1495-1500.
• [33]Xin W, Wei W, Li X: Effects of fish oil supplementation on cardiac function in chronic heart failure: a meta-analysis of randomised controlled trials. Heart 2012.
• [34]Tousoulis D, Charakida M, Stefanadis C: Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 2005, 100:347-353.
• [35]Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P: Systemic inflammation in heart failure–the whys and wherefores. Heart Fail Rev 2006, 11:83-92.
• [36]McKinsey TA: Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med 2011, 17:434-441.
• [37]Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
• [38]Pye M, Rae AP, Cobbe SM: Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 1990, 63:228-230.
• [39]Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994, 72:561-566.
• [40]Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723-727.
• [41]MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S: Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997, 79:1128-1131.
• [42]Andreassen AK, Nordoy I, Simonsen S, Ueland T, Muller F, Froland SS, Gullestad L, Aukrust P: Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998, 81:604-608.
• [43]Calder PC: n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83:1505S-1519S.
• [44]Calder PC: Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol 2011, 668(Suppl 1):S50-S58.
• [45]Myhrstad MC, Retterstol K, Telle-Hansen VH, Ottestad I, Halvorsen B, Holven KB, Ulven SM: Effect of marine n-3 fatty acids on circulating inflammatory markers in healthy subjects and subjects with cardiovascular risk factors. Inflamm Res 2011, 60:309-319.
• [46]Zhao Y, Joshi-Barve S, Barve S, Chen LH: Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr 2004, 23:71-78.
• [47]Duda MK, O'Shea KM, Stanley WC: omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res 2009, 84:33-41.
• [48]Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GI: Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006, 55:924-928.
• [49]Ouchi N, Walsh K: Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007, 380:24-30.
• [50]Osman R, L'Allier PL, Elgharib N, Tardif JC: Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag 2006, 2:221-237.
• [51]Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS: The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol 2008, 6:258-270.